[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letter-karcz-nation-llc-729916-09042026":3,"fda-latest-sync-dates":29},{"id":4,"letter_id":5,"action_type":6,"firm_name":7,"fei_number":8,"issuing_office":9,"subject":10,"posted_date":11,"action_taken_date":12,"response_letter_date":8,"closeout_date":8,"case_status":13,"letter_url":14,"reference_number":8,"marcs_cms_no":15,"product_type":16,"delivery_method":17,"recipient_name":18,"recipient_title":8,"body_html":19,"body_text":20,"body_fetched_at":21,"medical_device_id":8,"raw":22,"created_at":27,"updated_at":28},22197,"karcz-nation-llc-729916-09042026","Warning Letter","Karcz Nation, LLC",null,"Center for Veterinary Medicine","New Animal Drug\u002FAdulterated","2026-11-10","2026-09-04","Issued","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkarcz-nation-llc-729916-09042026","729916","Animal & Veterinary","VIA EMAIL NO HARD COPY TO FOLLOW","Jacob J. Karcz, Co-owner","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL NO HARD COPY TO FOLLOW\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jacob J. Karcz, Co-owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Dillon J. Karcz, Co-owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Karcz Nation, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>N. 3035 Willow Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pulaski\u003C\u002Fspan>, \u003Cspan>WI\u003C\u002Fspan> \u003Cspan>54162-7710\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 729916\u003C\u002Fp>\u003Cp>September 04, 2026\u003C\u002Fp>\u003Cp>Dear Messrs. Jacob and Dillon Karcz,\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your dairy farm, Karcz Nation, LLC., located at N. 3035 Willow Rd, Pulaski, WI 54162-7710, between March 30, 2026 and April 2, 2026. At the close of the inspection, you were issued a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge your written responses received April 27, 2026 and May 12, 2026, and address your proposed corrections below.\u003C\u002Fp>\u003Cp>This letter notifies you of the violations of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) that we found during our inspection of your operation. You can find the FD&amp;C Act and its associated regulations on the internet through links on FDA’s web page at www.fda.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulteration of Animals Offered for Human Consumption\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection found you offered for sale, animals for slaughter as food that were adulterated. Specifically, you sold the following animals for slaughter as food:\u003C\u002Fp>\u003Cul>\u003Cli>A cow identified with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was slaughtered on or about \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The United States Department of Agriculture\u002FFood Safety and Inspection Service (USDA\u002FFSIS) analysis of tissue samples collected from the animal identified the presence of ampicillin at 0.0224 parts per million (ppm) in kidney tissue.\u003C\u002Fli>\u003Cli>A cow identified with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> and backtag \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was slaughtered on or about \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at \u003Cstrong>(b)(4)\u003C\u002Fstrong>. USDA\u002FFSIS analysis of tissue samples collected from the animal identified the presence of desfuroylceftiofur at 1.07 ppm in kidney tissue and ampicillin at 0.0341 ppm in kidney tissue.\u003C\u002Fli>\u003Cli>A cow identified with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> and backtag \u003Cstrong>(b)(4)\u003C\u002Fstrong> on or about \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The animal was slaughtered on or about \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at \u003Cstrong>(b)(4)\u003C\u002Fstrong>. USDA\u002FFSIS analysis of tissue samples collected from the animal identified the presence of desfuroylceftiofur at 1.54 ppm in kidney tissue.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>FDA has established a tolerance of 0.01 ppm of ampicillin in edible tissues of cattle\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and has established a tolerance of 0.4 ppm of desfuroylceftiofur, a marker residue of ceftiofur drugs, in the kidney tissue of cattle.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The presence of these drugs in the edible tissues of these animals at these levels causes the food to be adulterated. A food is deemed to be adulterated if it bears or contains a new animal drug that is unsafe.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> A drug is unsafe if it results in any residues that exceed any established safe levels.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Additionally, our inspection found that you hold animals under conditions that are inadequate such that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. Specifically, you did not routinely maintain complete treatment records for drugs administered to cattle on your farm, including the dose, route of administration, identity of person administering medication, the withdrawal period of each drug, and the date when the withdrawal period is met based on the final treatment date. Food held under conditions whereby it may have been rendered injurious to health is adulterated.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulteration of a New Animal Drug\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection found you did not use \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Ceftiofur Crystalline Free Acid, NADA #\u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Ceftiofur hydrochloride, NADA #\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Ampicillin for injectable suspension, NADA #\u003Cstrong>(b)(4)\u003C\u002Fstrong>) as directed by their approved labeling. Use of a drug in a manner that is not consistent with its labeling is extralabel use.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our inspection found that you administered \u003Cstrong>(b)(4)\u003C\u002Fstrong> to cattle in an extralabel manner by not following its meat withdrawal time or dosage. During the inspection, your records and affidavit showed that you administered 30ccs of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for metritis in a cow with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This cow was sold for human consumption on or about \u003Cstrong>(b)(4)\u003C\u002Fstrong>, within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug meat withdrawal period. You stated in your signed affidavit that a cow with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> was approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The label directions state dosage is \u003Cstrong>(b)(4)\u003C\u002Fstrong> 100lbs body weight, indicating the maximum dosage per label directions for an animal this weight should be \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the animal was given a dose in excess of the drug labeling. Our investigation also found that you administered \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a cow with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and subsequently sold this cow for human consumption on \u003Cstrong>(b)(4)\u003C\u002Fstrong> within its drug meat withdrawal period. As described above, these animals were later reported by USDA\u002FFSIS to have a residues of desfuroylceftiofur in kidney tissues that exceeded established safe levels.\u003C\u002Fp>\u003Cp>Our inspection further found that you administer \u003Cstrong>(b)(4)\u003C\u002Fstrong> to cattle in an extralabel manner by not following its meat withdrawal time. Your affidavit and records stated you treated a cow with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> on January 29, 2026 and January 30, 2026. This cow was sold for human consumption on or about \u003Cstrong>(b)(4)\u003C\u002Fstrong>, within the four-day drug meat withdrawal period without keeping record of where you sold it.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, ceftiofur drugs that are part of the cephalosporin class of drugs, are prohibited from extralabel use at unapproved withdrawal period durations or dosages in food-producing animals.\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Cephalosporins are medically important antimicrobials critical to treating serious human infections. For this reason, FDA prohibits certain extralabel uses of cephalosporins (at unapproved doses, frequencies, durations, or routes of administration) in major food-producing animal species (cattle, swine, chickens, and turkeys).\u003Cem>\u003Cstrong>\u003Csup>9 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>Such prohibited extralabel uses may contribute to the emergence of antimicrobial-resistant bacteria and may have unknown microbiological or toxicological effects. The improper extralabel use of drugs, especially those prohibited from extralabel use, may result in illegal drug residues remaining in food, such as meat and milk, derived from treated food-producing animals.\u003C\u002Fp>\u003Cp>Our inspection further found that you administer \u003Cstrong>(b)(4)\u003C\u002Fstrong> to cattle in an extralabel manner by not following its meat withdrawal time and using it to treat for conditions and given at doses that are not consistent with the drug manufacturer’s approved labeling or veterinary prescription. During the inspection we found that a cow identified with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> was treated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> on October 30, 2025 for mastitis and sold for human consumption on \u003Cstrong>(b)(4)\u003C\u002Fstrong> within its six-day meat withdrawal period. A cow identified with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> was also treated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> on November 3, 2025 for metritis and sold for human consumption on \u003Cstrong>(b)(4)\u003C\u002Fstrong> within its meat withdrawal period. These animals were reported by USDA\u002FFSIS to have residues of ampicillin in edible tissues exceeding established safe levels.\u003C\u002Fp>\u003Cp>Additionally our inspection also found a cow identified with ear tag \u003Cstrong>(b)(4)\u003C\u002Fstrong> was treated with 35ccs \u003Cstrong>(b)(4)\u003C\u002Fstrong> on November 11, 2025 and November 21, 2025 for metritis and sold on \u003Cstrong>(b)(4)\u003C\u002Fstrong> within its meat withdrawal period. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not labeled or prescribed as a treatment for mastitis or metritis. Therefore, you did not adhere with the approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeling or your veterinarian’s prescription label.\u003C\u002Fp>\u003Cp>The extralabel use of these drugs is only allowed if it complies with the FD&amp;C Act and 21 CFR Part 530 including that such use must be by or on the lawful order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship.\u003Cem>\u003Cstrong>\u003Csup>10, 11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your extralabel use of these drugs in food producing animals was not under the supervision of a licensed veterinarian and resulted in residues above established safe levels, safe concentrations or tolerances.\u003Cem>\u003Cstrong>\u003Csup>12, 13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Because your use of these drugs was not in conformance with their approved labeling and did not comply with 21 CFR Part 530, you caused these drugs to be unsafe and adulterated.\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act.\u003Cem>\u003Cstrong>\u003Csup>15 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>The doing of any act to a drug after shipment of the drug and\u002For its components in interstate commerce and while the drug is held for sale (whether or not the first sale) that results in the drug being adulterated is prohibited.\u003Cem>\u003Cstrong>\u003Csup>16\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Evaluation of Your Response\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your written responses, received on April 27, 2026 and May 12, 2026 you explained your \u003Cstrong>(b)(4)\u003C\u002Fstrong> along with provided photographs. Your response explained an example cow that was treated for metritis with a three-day treatment protocol of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and included how this was established for diagnosis, dosage determination based on the size of the animal. In addition, you established a “Chore” column that noted dates of subsequent treatment and doses under the protocol and a “Meat Hold” date for that drug highlighted in red to prevent sale within withdrawal periods. Review of the written protocol for \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your system example appears to conform with the label directions for use.\u003C\u002Fp>\u003Cp>Furthermore, you stated that you will now keep shipping and sale documents on-hand as opposed to an off-site office for reference on where and when animals are sold and noted that you are implementing \u003Cstrong>(b)(4)\u003C\u002Fstrong> reviews of treatment documents with employees to ensure improved data entry to aid residue control. However, the documents you provided only contain a single example for your \u003Cstrong>(b)(4) \u003C\u002Fstrong>treatment protocol. We are unable to provide a comprehensive evaluation of your corrective actions on residue prevention, drug treatment record documentation, and extralabel drug use prevention regarding the other drugs noted above associated with the violative drug tissue residues reported by USDA\u002FFSIS.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Conclusion\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to regulatory, or where appropriate, legal action.\u003C\u002Fp>\u003Cp>For more information about FDA’s current thinking on the requirements of safely administering approved drugs to food-producing animals and use of cephalosporin drugs prohibited from extralabel use, see:\u003C\u002Fp>\u003Cp>• T.A.L.K. Before You Treat | FDA\u003Cbr>• Adequate Records Help Prevent Illegal Drug Residues and Ensure Food Safety\u003Cbr>• Cephalosporin Order of Prohibition Questions and Answers\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe you have complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>The FDA, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\u003C\u002Fp>\u003Cp>Please direct your electronic correspondence to Compliance Officer Dylan C. Grippi at dylan.grippi@fda.hhs.gov. If you are unable to submit your correspondence electronically, please direct it to the attention of Dylan C. Grippi, Compliance Officer, at the following address:\u003C\u002Fp>\u003Cp>U.S. Food and Drug Administration\u003Cbr>Center for Veterinary Medicine\u003Cbr>CPK1, 5001 Campus Drive\u003Cbr>College Park, MD 20740-3835\u003C\u002Fp>\u003Cp>If you have questions regarding this letter, please contact Compliance Officer Dylan C. Grippi by telephone at (301) 452-1608, or by email at dylan.grippi@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Isaac K. Carney\u003Cbr>Director of Food Compliance, Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>CC: Dr. Michael W. Dupor, DVM\u003Cbr>Valley Veterinary Clinic\u003Cbr>707 Woodland Plaza\u003Cbr>Seymour, WI 54165\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>See Title 21 Code of Federal Regulations, 556.40(b)(1) (21 CFR 556.40(b)(1)).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 556.113(b)(1)(i).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See section 402(a)(2)(C)(ii) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(ii)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>See section 512(a)(4)(B) of the FD&amp;C Act [21 U.S.C. § 360b(a)(4)(B)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5 \u003C\u002Fstrong>\u003C\u002Fem>See section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See section 402(a)(4) of the FD&amp;C Act [21 U.S.C. § 342(a)(4)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.3(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.41(a)(13)(ii).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9 \u003C\u002Fstrong>\u003C\u002Fem>See the Animal Medicinal Drug Use Clarification Act (AMDUCA) and its implementing regulations at 21 CFR Part 530\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> See section 512(a)(4) and (5) of the FD&amp;C Act [21 U.S.C. § 360b(a)(4) and (5)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.3(i)(1).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.11(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 530.11(d).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> Under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)], a new animal drug is deemed adulterated if it is unsafe within the meaning of section 512 of the FD&amp;C Act [21 U.S.C. § 360b].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem> See section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem> See section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL NO HARD COPY TO FOLLOW\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nJacob J. Karcz, Co-owner\n\nRecipient Title\n\nDillon J. Karcz, Co-owner\n\nKarcz Nation, LLC\n\nN. 3035 Willow Rd\n\nPulaski, WI 54162-7710\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nCMS # 729916\nSeptember 04, 2026\nDear Messrs. Jacob and Dillon Karcz,\nThe United States Food and Drug Administration (FDA) conducted an inspection of your dairy farm, Karcz Nation, LLC., located at N. 3035 Willow Rd, Pulaski, WI 54162-7710, between March 30, 2026 and April 2, 2026. At the close of the inspection, you were issued a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge your written responses received April 27, 2026 and May 12, 2026, and address your proposed corrections below.\nThis letter notifies you of the violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that we found during our inspection of your operation. You can find the FD&C Act and its associated regulations on the internet through links on FDA’s web page at www.fda.gov.\nAdulteration of Animals Offered for Human Consumption\nOur inspection found you offered for sale, animals for slaughter as food that were adulterated. Specifically, you sold the following animals for slaughter as food:\nA cow identified with ear tag (b)(4) that was slaughtered on or about (b)(4), at (b)(4). The United States Department of Agriculture\u002FFood Safety and Inspection Service (USDA\u002FFSIS) analysis of tissue samples collected from the animal identified the presence of ampicillin at 0.0224 parts per million (ppm) in kidney tissue.\nA cow identified with ear tag (b)(4) and backtag (b)(4) that was slaughtered on or about (b)(4), at (b)(4). USDA\u002FFSIS analysis of tissue samples collected from the animal identified the presence of desfuroylceftiofur at 1.07 ppm in kidney tissue and ampicillin at 0.0341 ppm in kidney tissue.\nA cow identified with ear tag (b)(4) and backtag (b)(4) on or about (b)(4). The animal was slaughtered on or about (b)(4), at (b)(4). USDA\u002FFSIS analysis of tissue samples collected from the animal identified the presence of desfuroylceftiofur at 1.54 ppm in kidney tissue.\nFDA has established a tolerance of 0.01 ppm of ampicillin in edible tissues of cattle1 and has established a tolerance of 0.4 ppm of desfuroylceftiofur, a marker residue of ceftiofur drugs, in the kidney tissue of cattle.2\nThe presence of these drugs in the edible tissues of these animals at these levels causes the food to be adulterated. A food is deemed to be adulterated if it bears or contains a new animal drug that is unsafe.3 A drug is unsafe if it results in any residues that exceed any established safe levels.4 The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act.5\nAdditionally, our inspection found that you hold animals under conditions that are inadequate such that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. Specifically, you did not routinely maintain complete treatment records for drugs administered to cattle on your farm, including the dose, route of administration, identity of person administering medication, the withdrawal period of each drug, and the date when the withdrawal period is met based on the final treatment date. Food held under conditions whereby it may have been rendered injurious to health is adulterated.6\nAdulteration of a New Animal Drug\nOur inspection found you did not use (b)(4) (Ceftiofur Crystalline Free Acid, NADA #(b)(4)), (b)(4) (Ceftiofur hydrochloride, NADA #(b)(4)), and (b)(4) (Ampicillin for injectable suspension, NADA #(b)(4)) as directed by their approved labeling. Use of a drug in a manner that is not consistent with its labeling is extralabel use.7\nOur inspection found that you administered (b)(4) to cattle in an extralabel manner by not following its meat withdrawal time or dosage. During the inspection, your records and affidavit showed that you administered 30ccs of (b)(4) for metritis in a cow with ear tag (b)(4) on (b)(4). This cow was sold for human consumption on or about (b)(4), within the (b)(4) drug meat withdrawal period. You stated in your signed affidavit that a cow with ear tag (b)(4) was approximately (b)(4). The label directions state dosage is (b)(4) 100lbs body weight, indicating the maximum dosage per label directions for an animal this weight should be (b)(4) and the animal was given a dose in excess of the drug labeling. Our investigation also found that you administered (b)(4) to a cow with ear tag (b)(4) on (b)(4) and subsequently sold this cow for human consumption on (b)(4) within its drug meat withdrawal period. As described above, these animals were later reported by USDA\u002FFSIS to have a residues of desfuroylceftiofur in kidney tissues that exceeded established safe levels.\nOur inspection further found that you administer (b)(4) to cattle in an extralabel manner by not following its meat withdrawal time. Your affidavit and records stated you treated a cow with ear tag (b)(4) with (b)(4) on January 29, 2026 and January 30, 2026. This cow was sold for human consumption on or about (b)(4), within the four-day drug meat withdrawal period without keeping record of where you sold it.\n(b)(4) and (b)(4), ceftiofur drugs that are part of the cephalosporin class of drugs, are prohibited from extralabel use at unapproved withdrawal period durations or dosages in food-producing animals.8 Cephalosporins are medically important antimicrobials critical to treating serious human infections. For this reason, FDA prohibits certain extralabel uses of cephalosporins (at unapproved doses, frequencies, durations, or routes of administration) in major food-producing animal species (cattle, swine, chickens, and turkeys).9 Such prohibited extralabel uses may contribute to the emergence of antimicrobial-resistant bacteria and may have unknown microbiological or toxicological effects. The improper extralabel use of drugs, especially those prohibited from extralabel use, may result in illegal drug residues remaining in food, such as meat and milk, derived from treated food-producing animals.\nOur inspection further found that you administer (b)(4) to cattle in an extralabel manner by not following its meat withdrawal time and using it to treat for conditions and given at doses that are not consistent with the drug manufacturer’s approved labeling or veterinary prescription. During the inspection we found that a cow identified with ear tag (b)(4) was treated with (b)(4) on October 30, 2025 for mastitis and sold for human consumption on (b)(4) within its six-day meat withdrawal period. A cow identified with ear tag (b)(4) was also treated with (b)(4) on November 3, 2025 for metritis and sold for human consumption on (b)(4) within its meat withdrawal period. These animals were reported by USDA\u002FFSIS to have residues of ampicillin in edible tissues exceeding established safe levels.\nAdditionally our inspection also found a cow identified with ear tag (b)(4) was treated with 35ccs (b)(4) on November 11, 2025 and November 21, 2025 for metritis and sold on (b)(4) within its meat withdrawal period. (b)(4) is not labeled or prescribed as a treatment for mastitis or metritis. Therefore, you did not adhere with the approved (b)(4) labeling or your veterinarian’s prescription label.\nThe extralabel use of these drugs is only allowed if it complies with the FD&C Act and 21 CFR Part 530 including that such use must be by or on the lawful order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship.10, 11 Your extralabel use of these drugs in food producing animals was not under the supervision of a licensed veterinarian and resulted in residues above established safe levels, safe concentrations or tolerances.12, 13\nBecause your use of these drugs was not in conformance with their approved labeling and did not comply with 21 CFR Part 530, you caused these drugs to be unsafe and adulterated.14 The introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act.15 The doing of any act to a drug after shipment of the drug and\u002For its components in interstate commerce and while the drug is held for sale (whether or not the first sale) that results in the drug being adulterated is prohibited.16\nEvaluation of Your Response\nIn your written responses, received on April 27, 2026 and May 12, 2026 you explained your (b)(4) along with provided photographs. Your response explained an example cow that was treated for metritis with a three-day treatment protocol of (b)(4) and included how this was established for diagnosis, dosage determination based on the size of the animal. In addition, you established a “Chore” column that noted dates of subsequent treatment and doses under the protocol and a “Meat Hold” date for that drug highlighted in red to prevent sale within withdrawal periods. Review of the written protocol for (b)(4) in your system example appears to conform with the label directions for use.\nFurthermore, you stated that you will now keep shipping and sale documents on-hand as opposed to an off-site office for reference on where and when animals are sold and noted that you are implementing (b)(4) reviews of treatment documents with employees to ensure improved data entry to aid residue control. However, the documents you provided only contain a single example for your (b)(4) treatment protocol. We are unable to provide a comprehensive evaluation of your corrective actions on residue prevention, drug treatment record documentation, and extralabel drug use prevention regarding the other drugs noted above associated with the violative drug tissue residues reported by USDA\u002FFSIS.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to regulatory, or where appropriate, legal action.\nFor more information about FDA’s current thinking on the requirements of safely administering approved drugs to food-producing animals and use of cephalosporin drugs prohibited from extralabel use, see:\n• T.A.L.K. Before You Treat | FDA\n• Adequate Records Help Prevent Illegal Drug Residues and Ensure Food Safety\n• Cephalosporin Order of Prohibition Questions and Answers\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe you have complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\nThe FDA, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\nPlease direct your electronic correspondence to Compliance Officer Dylan C. Grippi at dylan.grippi@fda.hhs.gov. If you are unable to submit your correspondence electronically, please direct it to the attention of Dylan C. Grippi, Compliance Officer, at the following address:\nU.S. Food and Drug Administration\nCenter for Veterinary Medicine\nCPK1, 5001 Campus Drive\nCollege Park, MD 20740-3835\nIf you have questions regarding this letter, please contact Compliance Officer Dylan C. Grippi by telephone at (301) 452-1608, or by email at dylan.grippi@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nIsaac K. Carney\nDirector of Food Compliance, Office of Surveillance and Compliance\nCenter for Veterinary Medicine\nU.S. Food and Drug Administration\nCC: Dr. Michael W. Dupor, DVM\nValley Veterinary Clinic\n707 Woodland Plaza\nSeymour, WI 54165\n________________________\n1 See Title 21 Code of Federal Regulations, 556.40(b)(1) (21 CFR 556.40(b)(1)).\n2 See 21 CFR 556.113(b)(1)(i).\n3 See section 402(a)(2)(C)(ii) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(ii)].\n4 See section 512(a)(4)(B) of the FD&C Act [21 U.S.C. § 360b(a)(4)(B)].\n5 See section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n6 See section 402(a)(4) of the FD&C Act [21 U.S.C. § 342(a)(4)].\n7 See 21 CFR 530.3(a).\n8 See 21 CFR 530.41(a)(13)(ii).\n9 See the Animal Medicinal Drug Use Clarification Act (AMDUCA) and its implementing regulations at 21 CFR Part 530\n10 See section 512(a)(4) and (5) of the FD&C Act [21 U.S.C. § 360b(a)(4) and (5)].\n11 See 21 CFR 530.3(i)(1).\n12 See 21 CFR 530.11(a).\n13 See 21 CFR 530.11(d).\n14 Under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)], a new animal drug is deemed adulterated if it is unsafe within the meaning of section 512 of the FD&C Act [21 U.S.C. § 360b].\n15 See section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n16 See section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].","2026-11-17T01:02:25.346+00:00",[23,24,25,9,10,26,26,26],"\u003Ctime datetime=\"2026-11-10T05:00:00Z\">11\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-04T04:00:00Z\">09\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkarcz-nation-llc-729916-09042026\">Karcz Nation, LLC\u003C\u002Fa>","","2026-11-17T01:02:03.701861+00:00","2026-11-17T01:02:25.542641+00:00",{"510k":30,"classification":31,"enforcement":32,"event":33,"event_backfill":34,"pma":35,"warning_letter":36},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]